Administrative

Note: Your privacy is very important to us. To better serve you, the form information you enter is recorded in real time.

Please Select One
If BUA is renewed or amended please fill-in current BUA# as it appears on the approval letter.
Department*
(For IBC use only)

Principal Investigator

Is the PI completing this application?*

Co-PI

Form Completer Information

Lab Personnel

Training Completed
Check all that apply
Training Completed
Training Completed
  Check all that Apply
Biosafety (CITI)
Biosafety UA (Skillsoft)
Biological Safety Cabinet (BSC)
Bloodborne Pathogens (BBP)
PPE (Skillsoft)
Dangerous Goods Regulations (DGR)
Plant Biosafety
Greenhouse Safety Operations
DURC (Dual Use Research of Concern)
Nanomaterials
Training Completed
Check all that apply
Training Completed
Training Completed
  Check all that Apply
Biosafety (CITI)
Biosafety UA (Skillsoft)
Biological Safety Cabinet (BSC)
Bloodborne Pathogens (BBP)
PPE (Skillsoft)
Dangerous Goods Regulations (DGR)
Plant Biosafety
Greenhouse Safety Operations
DURC (Dual Use Research of Concern)
Nanomaterials
Training Completed
Check all that apply
Training Completed
Training Completed
  Check all that Apply
Biosafety (CITI)
Biosafety UA (Skillsoft)
Biological Safety Cabinet (BSC)
Bloodborne Pathogens (BBP)
PPE (Skillsoft)
Dangerous Goods Regulations (DGR)
Plant Biosafety
Greenhouse Safety Operations
DURC (Dual Use Research of Concern)
Nanomaterials
Training Completed
Check all that apply
Training Completed
Training Completed
  Check all that Apply
Biosafety (CITI)
Biosafety UA (Skillsoft)
Biological Safety Cabinet (BSC)
Bloodborne Pathogens (BBP)
PPE (Skillsoft)
Dangerous Goods Regulations (DGR)
Plant Biosafety
Greenhouse Safety Operations
DURC (Dual Use Research of Concern)
Nanomaterials
Training Completed
Check all that apply
Training Completed
Training Completed
  Check all that Apply
Biosafety (CITI)
Biosafety UA (Skillsoft)
Biological Safety Cabinet (BSC)
Bloodborne Pathogens (BBP)
PPE (Skillsoft)
Dangerous Goods Regulations (DGR)
Plant Biosafety
Greenhouse Safety Operations
DURC (Dual Use Research of Concern)
Nanomaterials
 
1Biosafety (CITI) - UA affiliated CITI program training_Training for Investigators, Staff, and Students Handling Biohazards - MANDATORY
2Biosafety (Skillsoft) - Formal EHS-provided or approved training in the Principals and practices of biological safety, mandatory before beginning work; approved annual refresher training required.
3BSC - Biological Safety Cabinet training (mandatory for users of Biological Safety Cabinets; can be fulfilled via EHS training)
4BBP - Bloodborne pathogen exposure control training (if applicable, mandatory before beginning work, must be renewed annually).
5PPE - Personal Protective Equipment (EHS provided training through Skillsoft; must be renewed annually).
 This page is not subject to F.O.I.A.* requests
 

Conditions for Biological Use Authorization Approval

The Primary Investigator agrees to the following Assurances:

Assurances:
Check all that apply
Assurances:
Assurances:
  Check all that apply
Ensure personnel listed in this application have received or will receive appropriate, and documented, training in basic biosafety.
Ensure personnel listed in this application have received or will receive appropriate, and documented, training in bloodborne pathogens via the Skillsoft Academy (contact EHS) before any work begins on this project and at least annually thereafter.
Ensure that personnel listed in this application have received or will receive appropriate, and documented, training in safe laboratory practices and procedures for this protocol before any work begins on this project and at least annually thereafter.
Ensure that personnel listed in this application are aware of the PPE requirements for working with chemicals or biological materials and will enforce the PPE requirements in their area.
Follow the health surveillance practices as approved for this protocol and inform those working on the protocol about appropriate emergency assistance information for their location(s).
Inform Biosafety Officer and/or EHS of any research-related accident or illness as soon as possible after its occurrence.
Comply with the UA Biosafety Manual; with UA and UA system-wide biosafety policy and procedure, and with all other applicable laws and regulations (federal and state).
Comply with guidance set forth in the NIH Guidelines for Research Involving Recombinant DNA Molecules (NIH Guidelines).
Comply with guidance set forth in CDC: Biosafety in Microbiological and Biomedical Laboratories (BMBL), 6th edition.
Submit electronically (via BUA) a request for pre-approval from the Institutional Biosafety Committee for any significant deviations from the biohazard containment or personnel protection provisions of the approved BUA, or any modifications to the study or additions or deletions of personnel, facilities, recombinant or infectious agents, procedures or locations.

Explanation of Project

Title should match the title on the funding, if funded.
Project Abstract: In layman’s terms, please provide a description of the project's purpose, your research or teaching intentions, and a brief summary of your testing/experimental procedures. Include discussions of biological hazards and risk assessment information. (e.g., What are you doing? Why are you doing it? How will you test or assay your work? Who is the work hazardous to?)
Will this study be funded?*
Does this study require agency or regulatory permits*
If uncertain, please contact the BSO for assistance.
Please upload completed regulatory permits: this includes collection permits (domestic and international).*
No File Chosen
File uploads may not work on some mobile devices.
If uncertain, please contact the BSO for assistance.
Please indicate the purpose of this project.*
Are there any other committee approvals required?*
Check All that Apply
Indicate IRB and/or IACUC # separated by a comma

Hazard Control: Attach SOPs



Attachments
No File Chosen
File uploads may not work on some mobile devices.
Attach any SOP's or Documents relative to the project.
Attachments
No File Chosen
File uploads may not work on some mobile devices.
Attach any SOP's or Documents relative to the project.
Attachments
No File Chosen
File uploads may not work on some mobile devices.
Attach any SOP's or Documents relative to the project.
Attachments
No File Chosen
File uploads may not work on some mobile devices.
Attach any SOP's or Documents relative to the project.

Where will this project take place?

Building and Room
Building and Room
Lab Biosafety Level*

Project Information

Please select the category under which your project falls. Once you pick a category, you will be directed to category-specific information. 

  • For each of the selected categories, indicate whether or not you will be following the UA standard operating procedures for infectious agents.
    • If you indicate 'Yes', then you agree to and must follow the standard procedures.
    • If you indicate 'No', please supply a brief description of the procedures that you will follow and include a justification for deviating from the standard procedures.
Infectious Agents
Bloodborne Pathogens
Environmental Samples
Animals (Vertebrate/Invertebrate)
Transgenic Animals (Vertebrate/Invertebrate)
Plants (Non-Transgenic or Non-Infectious)
DNA/RNA
Recombinant/Synthetic DNA

Infectious Agents

Please provide information on how infectious agents are used (according to the category that applies to your project)

research with non-recombinant bacteria, viruses, yeasts, fungi, parasites, and/or prions. If yes, describe. Include genus, species, and activities)
Non-recombinant microorganisms are administered to animals (including insects, nematodes, etc.) If yes, describe. Include species, route and dose/concentration
Recombinant microorganisms are created or used. If yes, describe.
If you answered yes to any of the above, please select all modes of transmission/infection
Modes of transmission
Susceptible species include the following:
Does this project involve transgenic plants? If yes, provide genus and species.
Does this project include harvest of or work with seeds from transgenic plants? If yes, provide genus and species.
Does this project involve the use of transgenic plants in the field? If yes, describe:

Bloodborne Pathogens

If your project involves any of the following, please list the type and the source. 

Tissue, Blood and Body Fluids

Includes carcasses
Are tissues or cells transplanted between species? If yes, describe:

Culture of Primary Cells or Cell Lines

Human embryonic stem cells (hESCs)
Human induced pluripotent stem cells (iPSCs)
Mammalian Species
Non-Mammalian species

Bloodborne Pathogens

Does this project involve: drawing, processing, working with or storing human blood, tissue, cells, cell lines or body fluids visibly contaminated with blood or other potentially infectious materials?
drawing, processing, working with or storing human blood, tissue, cells, cell lines or body fluids visibly contaminated with blood or other potentially infectious materials?
Have you completed a site-specific BBP Exposure Control Plan?
If yes, this form is available from EHS.
Decontamination Procedures:
I will use 0.5% sodium hypochlorite (a 1:10 dilution of household bleach) to decontaminate equipment and work surfaces. In locations where bleach would cause corrosion, I will decontaminate with an iodophor (e.g., Wescodyne).

Environmental Samples

Samples collected from a native environment
If you are bringing in samples collected from a native environment, please select which type of sample
Please list the origin of this sample (e.g., Mobile, Alabama; Waste water treatment plant)

Animals (Vertebrate/Invertebrate)

If your project involves animals, please provide the following information. (along with housing, acquisition and possible hazards)

If yes, please also complete the DNA section of this form.
If you will be breeding the animal, please provide information about the process and procedures.
If tissues, fluids and cells will be translated between species, please provide more information on the process and procedures.

Recombinant/Synthetic DNA

If your project involves any of the following items, please provide a description of your work. 

Recombinant and Synthetic RNA/DNA
In the context of the NIH Guidelines, recombinant and synthetic nucleic acids are defined as: (i) molecules that a) are constructed by joining nucleic acid molecules and b) that can replicate in a living cell, i.e., recombinant nucleic acids; (ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules, i.e., synthetic nucleic acids, or (iii) molecules that result from the replication of those described in (i) or (ii) above.
Recombinant and Synthetic RNA/DNA
Recombinant and Synthetic RNA/DNA
  Check all that apply
NA This project does not involve work with recombinant or synthetic RNA/DNA.
Deliberate transfer of drug resistance into microorganisms (III-A-1)
Cloning of toxic molecules, LD50<100ng/kg (III-B-1)
Experiments that have been previously approved by NIH/OSP as Major Actions under the Guidelines (Appendix D)(letter from NIH/OSP Director or RAC should be attached)
Experiments Involving the Deliberate Transfer of Recombinant or Synthetic Nucleic Acid Molecules, or DNA or RNA Derived from Recombinant or Synthetic Nucleic Acid Molecules, into One or More Human Research Participants (III-C-1)
Experiments with pathogenic agents (Risk Groups 2, 3, 4 or restricted agents) as host vector systems (III-D-1)
Cloning DNA from pathogenic agents (Risk Groups 2, 3, 4 or restricted agents) into nonpathogenic prokaryotic or lower eukaryotic host-vector systems (III-D-2)
Use of infectious DNA or RNA virus or defective DNA or RNA virus in the presence of a helper virus in tissue culture systems (III-D-3)
Experiments involving recombinant DNA and whole animals (vertebrate or invertebrate), including breeding and colony maintenance of transgenic strains. (III-D-4)
Experiments involving recombinant DNA in whole plants, including genetically engineering the plants, using such plants for other experimental purposes (e.g., response to stress), the propagation of such plants, using plants together with microorganisms or insects containing recombinant or synthetic nucleic acid molecules (III-D-5)
Large-scale (>10L culture) experiment or production of recombinant host or vector (III-D-6)
Experiments with influenza viruses (III-D-7)
Experiments involving recombinant or synthetic DNA not included in previous sections and generally carried out at BSL-1 containment per NIH Guidelines (III-E).
Experiments involving the formation of recombinant or synthetic nucleic acid molecules containing no more than two-thirds of the genome of any eukaryotic virus (III-E-1)
Experiments involving whole plants if those experiments involving nucleic acid molecule-modified whole plants, and/or experiments involving recombinant or synthetic nucleic acid molecule-modified organisms associated with whole plants do not fall into a previously identified category. (III-E-2)
Experiments involving transgenic rodents (III-E-3)
Recombinant or synthetic DNA work that is exempt from the Guidelines per III-F or Appendix C. Please give the justification for exemption:
Recombinant/Synthetic DNA Training

Please Provide Information in the areas below that pertain to your specific genetic research.

Construction and/or use of synthetic DNA/RNA (e.g., probes, DNA or RNA oligonucleotides, base-pair analogs) Describe all biological reagents (e.g. plasmids, cell lines, prokaryotic hosts) that will be used in the experiment. Describe the types of recombinant DNA manipulations to be performed and the biosafety containment levels at which each of these operations will occur Describe the gene (genomic or cDNA), the bacterial plasmid or phage vector, and the delivery vector (if any). Provide complete nucleotide sequence analysis or a detailed restriction enzyme map of the total construct. What regulatory elements does the construct contain (e.g., promoters, enhancers, polyadenylation sites, replication origins, etc.)? From what source are these elements derived? Summarize what is currently known about the regulatory character of each element.
What is the structure of the cloned DNA that will be used? Describe the types of recombinant DNA manipulations to be performed and the biosafety containment. What regulatory elements does the construct contain (e.g., promoters, enhancers, polyadenylation sites, replication origins, etc.)? From what source are these elements derived? Summarize what is currently known about the regulatory character of each element.
What is the structure of the cloned DNA that will be used? Describe the types of recombinant DNA manipulations to be performed and the biosafety containment e.g. (prokaryotic hosts for DNA replication, prokaryotic hosts for protein production and isolation, eukaryotic cell transfections for promoter analysis). What regulatory elements does the construct contain (e.g., promoters, enhancers, polyadenylation sites, replication origins, etc.) From what source are these elements derived? Summarize what is currently known about the regulatory character of each element.
Use of recombinant or synthetic DNA/RNA in microorganisms that are exempt under NIH guidelines, Section III-F. Please list strains.
Use of recombinant or synthetic DNA/RNA in non-exempt microorganisms. Please list genus, species and strains (e.g., lentiviral vectors, agrobacterium)
Use of recombinant of synthetic DNA/RNA in animals (somatic cells or germ-line transgenics) including insects, nematodes and mammals. Describe and list species.
Use of recombinant or synthetic DNA in plants (somatic cells or germ-line transgenics)
Use of recombinant or synthetic DNA/RNA in cell culture. Please list species.
If there is a potential for toxic products to be produced/released from recombinant cells, animals or plants. List the toxic products and how they function. The definition of toxic is an agent with a LD(50) of less than 100 nano grams per kilogram (ng/kg) body weight
If there is a potential for infectious agents to be produced/released from recombinant cells, animals or plants, please explain.
If there will be an environmental release or field testing of genetically engineered organisms, please explain.
If there will be negative replication competent virus testing on viral vectors, please submit results.
Enhanced gene delivery (e.g., GeneGun, Gene Therapy techniques)
This project includes research with recombinant or synthetic DNA/RNA with the following enhanced gene delivery techniques:
Describe the role of enhanced gene delivery in this work.
Biological Toxins
Release of biological toxins (NIH Guidelines, Section III-B-1 and Appendix F)
Antibiotic or Herbicide: Will you introduce resistance to the germline?
Antibiotic/herbicide resistance (NIH Guidelines, Section III-A)
Increased Tropism
Increase of tropism (NIH Guidelines, Appendix B-V)
Increased Virulence
Increase of virulence (NIH Guidelines, Section II-A-3)

Health:Protection or Surveillance and Post Exposure

Health protection, health surveillance and post-exposure treatment programs to be used in this project

If needed, consult medical professionals BEFORE completing the Biological Use Authorization application.  All surveillance, vaccination, post-exposure treatment, and PPE clearance and fit-testing services are to be provided at no cost to the employee.  

    

Health Protection/Surveillance and Post Exposure Treatment Program Planned*
Health: Protection or Surveillance and Post Exposure
Health:Protection or Surveillance and Post Exposure
Health:Protection or Surveillance and Post Exposure
  Check all that apply
Bloodborne pathogens: HBV vaccination (or declination) on file with EHS, post-exposure follow-up and treatment, vaccination record retention by Principal investigator, initial BBP training and annual retraining, and universal precautions, BBP exposure control plan attached
HIV post-exposure prophylaxis: Post-exposure treatment with anti-retroviral drugs within two hours, with medical follow-up
Orthopoxviruses (vaccinia and others): Medical screening, vaccination and contraindication awareness, and training
Prion research: Training and special procedures for exposure reporting, decontamination and records handling
Cercopithecine herpesvirus-1 (Herpesvirus simiae, Herpes B): Initial training and post potential exposure follow-up and treatment
Health history form: Consult with EHS
Respirator clearance and fit-testing: Clearance from medical personnel and fit-testing at EHS
Custom health surveillance/immunization program will be adopted: Please describe the plan in the appropriate headings of Section 2C, 2D, or 3. Be sure to obtain medical approval before submitting the plan to the IBC
Other:

Risk Minimization/Disposal/Transportation

Biohazard containment and risk reduction.  

Identify measures you will employ to contain biohazardous materials and transgenic animals in such a way as to prevent researcher, community, or environmental exposure to biohazardous agents, recombinant DNA, and contaminated material.   

Lab Access*
Sharps Safety*
Please indicate which manipulations will involve sharps. Please indicate what would happen immunologically in the event of auto-inoculation (with the agent or genes of interest).
Do you plan to use a Biological Safety Cabinet (BSC)*
If yes please give class, type and location
Centrifugation Safety*
Check all that apply
Safety Practices to minimize aerosols*
Please indicate all procedures that involve the potential generation of aerosols (e.g., sonication; aspiration of media; vortexing; work with LN2-frozen cell lines).
Please indicate how you will contain aerosols (e.g. use of a biological safety cabinet; barrier pipette tips).
Safety practices pertaining to animal work
For other animal-related safety practices, please describe:
Safety Practices pertaining to plant work
For other plant-related safety practices, please describe:
Personal Protective Equipment (PPE) in addition to proper lab attire.*
UA minimum PPE requirement is: safety glasses, gloves, and lab coat anywhere chemical or biological materials are used or stored unless otherwise justified by risk assessment and approved by the Biosafety Officer.
Please list the appropriate PPE required for each type of work. (e.g, lab coat, gown, scrubs, gloves, safety glasses, goggles, face shield, surgical mask, respirator, hair net, shoe covers).
Disposal Practices: Check all that apply*
Terminal inactivation and waste disposal. Indicate your methods for terminal inactivation of the biological agent or transgenic material (microorganisms, animals, plants, plant transformation agents, tissues, etc). If generating multiple types of waste please clarify what waste is being disposed of in the text field (i.e. rDNA, infectious, transgenic material, etc.). If an autoclave will be used to inactivate waste (liquid or solid), the autoclave must be tested according to ADEM Admin. Code r. 335-13-7-08 as referenced in the UA Biosafety Manual.
Indicate if EHS will be called to pick up the waste for final disposal.
Transport and shipping. Indicate any transport of biohazardous materials (human, animal, and plant pathogens), transgenic materials (cell lines, microbes, plants, etc), and other materials, including origin and destination laboratories or other facilities, frequency of transport, and measures you will employ to prevent accidental release of biohazardous materials.
When transporting materials within (or between) facilities, we will use secondary containers that are sturdy, leak-proof, lidded, labeled appropriately (with a biohazard symbol if material is handled at BSL2 or above), with enough absorbent material to absorb any spill.
When transporting or shipping biomaterials to OFF campus facilities, we will use secondary, rigid, leak-proof, triple-packaging, labeled appropriately (with a biohazard symbol if material is handled at BSL2 or above), with enough absorbent material to absorb any spill.
Attach a copy of Materials Transfer Agreement (MTA) or any additional shipping certification
No File Chosen
File uploads may not work on some mobile devices.
MTA is needed when the material is infectious, hazardous or subject to special regulations. If in doubt, contact the BSO or Office for Research & Technology Agreements (ORTA).
Use your mouse or finger to draw your signature above
Use your mouse or finger to draw your signature above
Use your mouse or finger to draw your signature above
Appendix A*

Appendix A.  University of Alabama Policies and Standard Operating Procedures for work with biohazardous agents

Note: Your signature on Page 1 of the BUA Application affirms that you have reviewed the material in this appendix and agree to abide by all of its provisions.

  1. Training
    • Only those persons who are adequately trained may work with biohazardous materials (human, animal, plant, environment) at UA or its satellite laboratories.  This standard includes all students, staff, and faculty involved with the project including the Principal investigator, and includes visiting scholars and volunteers. 
    • Short-term visitors to the laboratory (<1 day) who might be inadvertently exposed to biohazardous materials must receive PI-supplied information regarding the nature of the hazards, measures required for avoiding exposure, procedure for post-exposure treatment and follow-up, and the PI’s contact information.  
    • Basic biosafety, bloodborne pathogen control, medical waste management, as well as the “NIH Guidelines for Research Involving Recombinant or Synthetic DNA” training are available from UA Environmental Health and Safety.  Training in these topics must be renewed annually.  More specialized training may be available).  
    • Advanced Biosafety training is available through UA affiliation with the CITI program: Training for Investigators, Staff, and Students Handling Biohazards.
    • The Principal investigator is responsible for all lab- and project-specific training, including experimental methods and techniques; specific hazards associated with the project components; methods employed to reduce risks to an acceptable level; available project-specific medical surveillance and treatment; and training in the use and care of lab equipment. 
    • The training record should include a list of topics covered and materials used (such as the approved BUA), and the trainer and trainee should both sign the training record sheet.  
      • All training, including short-term visitor orientation, must be documented.  
      • A written quiz or some other method of evaluating trainee comprehension should also be included in the training and training documentation.
  2. Shipping and Receiving
    • All shipments (domestic and international) of biological materials must follow university policy and all applicable federal and international regulations and permitting requirements.  
    • Biohazardous materials may not be personally transported to or from campus unless specifically authorized by the IBC in your approved BUA and packaged to comply with current DOT, IATA, and public health agency guidelines, standards and regulations.  
    • Biohazardous materials may not be transported in private vehicles unless authorized by the IBC. SOP will be required.
    • Export of etiologic agents or recombinant DNA constructs may require federal agency permits (USDA, US Department of Commerce).  
    • Shipments of Biohazardous materials that have not yet been approved for use by the IBC should be shipped to EHS until IBC review is complete and approval for use is granted.
  3. Local Transport of Infectious Materials (on campus)
    • Intracampus transport of infectious materials must be specifically authorized by the IBC as part of your approved BUA protocol. 
      • Biohazardous materials transported between laboratories or to other on-campus facilities must be packaged in absorbent material (enough to absorb the entire liquid volume of the biohazardous material) in a primary leak-proof container with a sealed lid or top, which is enclosed in a secondary leak-proof, non-breakable container (e.g., a Coleman cooler) appropriately labeled with the biohazard symbol (for human biohazards). 
  4. Personal Protective Equipment (PPE)
    • Wear appropriate PPE such as gloves, safety glasses and a laboratory coat whenever you work with biohazardous materials. Specific PPE requirements are determined by risk assessment of the research. 
  5. Footwear
    • No open-toed or open-heeled shoes or sandals are allowed in the laboratory. A good practice is to keep a set of lab-dedicated closed-toed, closed-heeled shoes at the laboratory work site. Change into them when you arrive at the lab, and change back to street shoes when you are ready to leave the building.
  6. Hand washing
    • After working with biohazardous materials remove your gloves immediately and wash your hands with soap and water. If soap and water are not available (such as in field work locations), use disinfectant hand wipes.
  7. Use of sharps
    • Minimize the use of sharps with biohazardous materials. Wherever possible, replace glassware with plasticware.  
    • Never recap, bend or shear needles.
    • Use only hard-walled sharps containers and do not overfill. 
    • Keep sharps containers readily available in all locations where sharps waste may be generated.  
    • Any programmatic use of sharps in a biological safety cabinet should be documented by a risk assessment that shows that no other alternative is acceptable and that details additional training to safeguard the users. 
  8. Plastic sharps
    • The Biological Safety Office recommends strongly that plastic pipettes and pipette tips contaminated with agents biohazardous to humans be disposed in a hard walled red sharps container. 
    • Medical waste bags used for pipette tip disposal must conform to current regulatory agency bag color and strength standards.  
    • Medical waste must be disposed of in the approved medical waste stream.
  9. Food and Beverage
    •  Eating, drinking, storing food and drink for human consumption, smoking, applying cosmetics or lip balm and handling contact lenses in the laboratory are prohibited in all UA laboratories.
  10. Aerosol Generation
    •  Procedures that could generate biohazardous aerosols must be performed in a certified biological safety cabinet or equivalent approved containment device.  
    • Experimental systems at BSL1 containment (no demonstrable biohazard to humans, plants, or animals) are exempted from this requirement unless specified in permit conditions for the organism
  11. Safe use of biological safety cabinets
    •  Specific training in the safe use of biological safety cabinets is required for all users of these protective devices. EH&S offers a class that satisfies this training requirement.
    • Biological safety cabinets should be situated as far from doorways and common use walkways as possible. 
    • All biological safety cabinets must be certified under the NSF49 standard before first use, annually thereafter, and after the cabinet has been relocated or repaired and certification records must be on file with EHS. 
    • Biological safety cabinets used for containment of Risk Group 2 microbiological agents use must be decontaminated by an approved method before being relocated or decommissioned. EHS must approve and coordinate vendors for decontamination. 
    • Only one person at a time may use a biological safety cabinet. 
    • Open flames are prohibited in biological safety cabinets. 
    • Never work in a biological safety cabinet when the UV light is energized, and never operate the UV light with the sash open. 
      • Good practice: use the UV light only when the laboratory is unoccupied. 
      • Best practice: do not use the UV light—studies have shown UV to be an ineffective method of decontaminating biological safety cabinets and presents significant hazards to laboratory occupants.
  12. Proper Labeling
    • EHS will place universal biohazard label  and hazard signage adjacent to the doorways where biohazardous materials that are infectious to humans are used. The BSO will supply BSL2 labs with signage that is specific to the organisms within the lab. (Orange) 
    • Also lab personnel should label work areas, containment cabinets, and equipment including freezers, refrigerators, incubators, centrifuges, shakers, etc. with the biohazard label. 
    • Permitting agencies may also require door and equipment labeling for microbial agents not normally biohazardous to humans. 
    • Transgenic plants and animals must be labeled in a way to distinguish them from wildtype (unaltered) plants or animals. 
  13. Decontamination Procedures, General 
    • Use a spray bottle of 10% solution of household bleach in water (made fresh daily) to decontaminate equipment and work surfaces. Where bleach could cause corrosion (stainless steel surfaces), use an iodophor such as Wescodyne, or wipe away the sprayed bleach and spray 70% ethanol on the surface. 
    • Decontaminate liquids by adding bleach to a final concentration of 10%, with a 30 minute contact time. Quaternary ammonium disinfectant may be used to disinfect greenhouse benches and materials exposed to plant pathogens. Follow manufacturer label instructions to disinfect solid non-porous surfaces and materials.
  14. Spills 
    • Any spill involving infectious agents or recombinant DNA must be reported immediately to the Biological Safety Officer and/or EHS.
  15. Risk Group 2 agent spill outside of a biological safety cabinet
    •  Let the spill “settle” for at least 30 minutes, evacuate the laboratory, and post signs on the doors to prevent re-entry before it is safe. Wear lab coat or Tyvek gown, gloves, goggles, and (at minimum) a surgical mask to clean biohazardous spills outside of a biological safety cabinet. 
    • Wear a properly fit-tested respirator (at least N95) to clean Risk Group 2 agent spills if aerosol infection is possible (including plasmids with oncogenes). 
    • Distribute paper towels around the periphery of the spill, then proceed towards the center of the spill. 
      • When the spill is fully contained, spray 10% bleach or other approved disinfectant on the paper towels, allow 30 minutes contact time, and clean up the paper towels with large forceps. 
      • Change gloves, and spray 10% bleach or other approved disinfectant on the surface residue.  
      • Wipe up the residue with paper towels and repeat at least once.  
      • Dispose all of the paper towel waste in a medical waste bag. 
  16. Risk Group 2 agent spill inside of a biological safety cabinet 
    • Always ensure that the bottom drain is closed before working at a biological safety cabinet. 
      • If the spill occurs both inside and outside of the BSC, first employ the 30 minute 'settle time' standard BEFORE beginning cleanup procedures. 
    • Use the same techniques described above regarding paper towel placement and disinfectant use.
    • If 10% bleach is used to decontaminate the spill on a stainless steel surface, spray 70% ethanol and wipe surfaces dry with paper towels.
  17. Mouth Pipetting 
    • Mouth pipetting may lead to accidental ingestion of biohazardous material and is strictly prohibited.
  18. Storage 
    • Store all biohazardous materials in containers clearly labeled with the universal biohazard symbol. Permanently label stored biohazardous material with common names wherever possible, in addition to lab-specific codes.
  19. Waste
    • If your work results in the production of medical waste (materials in contact with human or non-human primate tissue, and other waste known or suspected to harbor human infectious agents or potentially harbor such agents naturally), you conform to the UA Medical Waste Management Plan. 
    • Medical waste must be autoclaved in a unit certified to handle medical waste or must be transported to a medical waste accumulation site for disposal in the medical waste stream.
    • Research lab dry waste known or suspected to harbor infectious agents (animal or plant) must also be accumulated in sturdy (non-red) bags and autoclaved (autoclave maintained at the medical waste standard is recommended) before disposing in the landfill.
      • Deface all biohazard symbols before disposing autoclaved biohazardous waste to the landfill.  
      • “Biotechnology waste” (with NIH-exempted cloning hosts such as E. coli K-12 or Saccharomyces cerevisiae but free of all infectious agents) can be accumulated in clear autoclave bags (deface any imprinted biohazard symbols) and must be autoclaved before disposal in the landfill.
    • As discussed above, liquid waste of any kind that is contaminated or potentially contaminated with any viable agent (infectious or non-infectious) must be decontaminated by 30 minutes exposure to 10% (final concentration) household bleach before it is disposed in the sanitary sewer.
  20. Autoclaves and autoclave safety
    • The standard autoclave sterilization process is 30 minutes exposure at 121ºC (250º F). This measure is intended to reflect the temperature and pressure conditions at the center and throughout the load, not the outside edges.  Large volumes of material can require longer exposure times.  
    • Always use a sterilization indicator such as autoclave tape.
    • Always wear heat-resistant gloves, goggles or safety glasses, and a laboratory coat when opening an autoclave. Be sure to allow the superheated steam to dissipate before attempting to remove the autoclave contents.
    • All autoclave usage and maintenance should be per ADEM Admin. Code r. 335-13-7-08. 
    • Prions can only be inactivated by incineration (BMBL 6th). The use of prions or suspected prions requires IBC approval before work may begin.
  21. Incidents, injuries, and health emergencies
    • Report all injuries and accidental autoinoculation, ingestion or inhalation of infectious agents to the lab director or supervisor, and the Biological Safety Officer. 
    • Follow the UA policies for medical evaluation and possible treatment. 
      • Dial 911 (or 205-348-5454) immediately for any medical emergency.  
      • After normal business hours and on weekends, DCH handles UA employee health emergencies. 

Any spill, needle stick, or other exposure or release involving infectious agents or recombinant DNA must be reported immediately to the Biological Safety Officer! 

Emergencies.  During natural disasters, fires, power failures, bomb threats, major biohazardous spills, or other emergencies, take the following precautions and evacuate the lab by posted or ordered evacuation routes

  1. Secure infectious materials as quickly as possible.  If a biological safety cabinet is being used, close all containers and, if possible, close the sash.
  2. Call 911 (or 205-348-5454) and request emergency response. 
  3. When the incident is resolved, if the building is safe to enter (at the direction of the incident commander), proceed to the lab, don appropriate PPE, and assess the lab for the disaster-related release of infectious material. Use the above spill control procedures to contain released material.
  4. Report any spills involving infectious agents or recombinant DNA to the Biological Safety Officer immediately!

 

Confirmation Page

{$25068397 Safety Practices to minimize aerosols} {$25113124 Aerosol Safety} {$25113148 Aerosol Safety} {$25068437 Safety practices pertaining to animal work} {$25068497 Safety Practices pertaining to plant work} {$25068559 Personal Protective Equipment(PPE)} {$25114329 PPE} {$25071267 Disposal Practices} {$25071295 Transport Practices} {$25071482 Transport} {$25194580 Transport} {$25071798 Attach a copy of MTA or any additional shipping...} {$25124325 Principal Investigator} {$28083416 Co-Principal Investigator (Shared Space)} {$28083281 Biological Safety Officer/ Manager} {$28083410 IBC Chair} {$25124386 Appendix A} {$24548615 Recombinant of synthetic DNA/RNA in animals} {$24548653 Recombinant or synthetic DNA in plants} {$24548659 Recombinant or synthetic DNA/RNA in cell culture} {$24548668 Toxic product or release} {$24548740 Infectious Agents} {$24548772 Environmental Release or Field Testing} {$24548885 Negative replication competent virus testing} {$24548817 Enhanced gene delivery} {$24548938 Enhanced gene delivery (continued)} {$24548939 Biological Toxins} {$24549031 Antibiotic or Herbicide } {$24549035 Increased Tropism } {$24549049 Increased Virulence } {$25067395 Lab Access} {$25067995 Sharps Safety} {$25068176 Please describe all sharps safety practices in...} {$25084373 Biological Safety Cabinet(BSC)} {$25084460 BSC Type and Location} {$25068062 Centrifugation Safety} {$24313202 Review Date} {$24310424 PI Name} {$24310659 Lab Location} {$24310579 Office Location} {$21891688 Phone } {$21891691 Email} {$29220582 Email - Copy} {$22107443 Co-PI} {$24310781 Co-PI Email} {$24310746 Co-PI Phone} {$24311031 Name of person completing form} {$24311049 Form Completer Phone} {$24311033 Form completer email} {$25125457 Name/Status} {$25125077 Email} {$25125116 Training Completed} {$24311996 Name/Status} {$25125128 Email} {$25125460 Training Completed} {$22107488 Name/Status} {$25125127 Email} {$25125470 Training Completed} {$22107507 Name/Status} {$25125126 Email} {$25125477 Training Completed} {$24312331 Name/Status} {$25125125 Email} {$25125474 Training Completed} {$23872295 Assurances} {$22106622 Project Title} {$22106623 Project Abstract} {$24314705 Will this study be funded?} {$22106642 Funding Agency:} {$22106644 Award #:} {$22106646 Start/End Dates:} {$24312570 Are there any agency permits required?} {$25088629 Regulatory Permits} {$24312640 Are there any other committee approvals required?} {$29220686 Attachments} {$24312804 Lab Location} {$24312811 Support Rooms} {$25084762 Lab Biosafety Level} {$24545445 If no give} {$24316421 Infectious Agents} {$24316593 Bloodborne Pathogens} {$24316604 Environmental Samples} {$24316610 Animals (Vertebrae/Invertebrae)} {$25194975 If Yes, insert IACUC Protocol #} {$24316618 DNA/RNA} {$24545597 This project involves:} {$24545670 Non-recombinant microorganisms} {$24545884 Recombinant microorganisms} {$24545926 If you answered yes to any of the above} {$24545930 Susceptible species include the following:} {$24546097 Transgenic Plants} {$24546113 Transgenic Plants(seeds)} {$24546140 Transgenic Plants (field use) } {$24546303 Humans} {$24546308 Laboratory animals} {$24546313 Non-human primates} {$24546341 Wild animals} {$24546343 Other} {$24546346 Tissue or Cell Transplantation} {$24546461 Human} {$24546466 Stem Cells} {$24546584 Stem Cells} {$24546590 Non-human primate} {$24546593 Other } {$24546595 Other} {$24546626 Does this project involve the following:} {$24546740 Have you completed a site-specific BBP Exposure...} {$24316393 Decontamination Procedures: } {$25084719 Health Protection/Surveillance and Post...} {$25072328 Health:Protection or Surveillance and Post...} {$24547847 Samples collected from a native environment} {$24548076 Species} {$24548083 Is the animal transgenic? Please describe the...} {$24548115 Breeding} {$24548133 Tissues, fluids and cells will be translated...} {$25122842 Recombinant and Synthetic DNA} {$25123343 Exempt under III-F or Appendix C} {$25123095 Recombinant/Synthetic DNA Training} {$24548325 Construction and/or use of synthetic DNA/RNA } {$24548461 Creation of c-DNA/genomic libraries} {$24548462 DNA/RNA sequencing} {$24548468 Recombinant or synthetic DNA/RNA in...} {$24548495 Recombinant or synthetic DNA/RNA in non-exempt...} {$_submission_id} {$_submission_time} {$29222910 Application Type} {$32628973 Department} {$29220586 Current BUA #}

Save and Resume Later
Progress
Form secured by Formstack
Form secured by Formstack
Powered by Formstack Create your own form ›
Cancel
Confirm